Company news

Spyre Therapeutics, Inc. news in 2020

Spyre Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors

December 16, 2020

Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria

November 30, 2020

Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference

November 23, 2020

Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences

November 16, 2020

Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights

November 4, 2020

Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria

October 25, 2020

Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings

October 4, 2020

Aeglea BioTherapeutics to Participate in September Investment Conferences

September 1, 2020

Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020

August 17, 2020

Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights

August 9, 2020

Aeglea BioTherapeutics to Present at BIO Digital 2020

May 31, 2020

Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020

May 27, 2020

Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology

May 25, 2020

Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology

May 18, 2020

Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights

May 6, 2020

Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 29, 2020

Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering

April 27, 2020

Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

April 7, 2020

Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones

February 23, 2020

Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

January 12, 2020

Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

January 5, 2020

Decks in 2020